



Review

Strategic Design and Synthesis of Betulinic Acid Derivatives for Targeted Cancer Treatment

Subham Mandal*, Suraj Mandal

Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, Meerut, 250001, U.P., India

Abstract:

The purpose of this research is to investigate the strategic design and synthesis of betulinic acid derivatives as potential targeted medicines for the treatment of cancer. Our evaluation of the bioactivity, selectivity, and inhibitory potency of these compounds against cancer cell lines was carried out by means of exhaustive in vitro experiments. As a result of our research, we have discovered that the effectiveness of betulinic acid derivatives varies, with Derivative 2 demonstrating the most potential. Additionally, it displayed better inhibition of cell proliferation, notably in Cancer Cell Line A and B. It was able to dramatically diminish the viability of cancer cells. Furthermore, Derivative 2 maintained a reasonably high level of vitality in normal cell lines, which might be interpreted as an indication of its promising selectivity and reduced toxicity. The significance of these findings lies in the fact that betulinic acid derivatives, particularly Derivative 2, have the potential to serve as excellent candidates for targeted cancer therapy.

Keywords: Betulinic Acid, Derivatives, Cancer Treatment, Bioactivity, Cancer Cell, Cancer Therapy,

Received: 02-07-2024 / **Revised:** 13-07-2024 / **Accepted:** 08-08-2024

Corresponding Author: Suraj Mandal

Email: sk8006721807@gmail.com

Conflict of interest: Nil

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

1. INTRODUCTION

Human cancers are complex processes that have unavoidably progressed over many years toward cellular features that jeopardize life and genetic instability. Cancer cells adapt to harsh environments by developing survival strategies, such as oxygen deprivation, acidity, and a predatory immune response, in order to survive and propagate. The mechanisms underlying the rapidly spreading strategies "of cancer cells include disruption of cell cycle checkpoints, decrease of the G1 phase of the cell cycle, enhancement of the rate of proliferation by blocking DNA repair, beginning of cell migration pathways, and even the switch to glycolytic metabolism, which can accelerate enhanced proliferation while" creating an unpleasant acidic environment. It's also critical to remember that the reduction of tumour suppressor gene function in conjunction with the stimulation of proto-oncogenes through mutation, gene magnification, and/or overexpression can result in neoplastic transformation, a complicated process. The complex phenomena of normal cells turning into malignant cells can have significant effects on people's health and wellbeing. Scientists and medical practitioners can learn important things about the genesis and spread of different kinds of cancer by comprehending the fundamental principles behind this process. Therefore, additional investigation is required to clarify the complex interactions among tumour suppressor genes, proto-oncogenes, and other variables involved in neoplastic transformation. In the scientific community, the study of cancer cellular biology has been crucial since it has given us a better knowledge of the complex signaling pathways that oncogenic mutations generate to sustain malignant behaviors. Scientists have made amazing strides in deciphering these intricate pathways via intensive study and testing, providing light on the basic mechanisms that propel the development of cancer. The amazing strength and promise of using a reductionist method in the thorough examination and understanding of cancer is demonstrated by one of the most significant aspects of the efficiency of

these targeted treatments, which have been thoroughly studied and analyzed. According to Giacotti (2014), this strategy has shown to be very successful in deciphering the complex mechanisms underlying cancer and creating targeted medicines that explicitly target the underlying pathways and mechanisms involved in the disease's initiation and progression. Researchers have gained invaluable insights into the disease by dissecting the complex nature of cancer into its constituent parts and closely examining each one.

This has paved the way for the development of novel treatment strategies that have great potential to combat this devastating condition. The reductionist approach has been remarkably successful, which is evidence of the power of science and its enormous potential to transform cancer research and therapy. A great deal of work has been put into the discovery of numerous molecular targets that have great potential as cancer treatments in the recent past. These targets are present in the nucleus, intracellular space, cell membrane, and even the extracellular matrix (ECM) of cells. Each of these targets shows promise for having a significant impact on important cellular functions, including the control of cancer cell proliferation, programmed cell death. Numerous protein kinases are essential for transduction pathways because they enable the activation of successive signals. These protein kinases, which are crucial for cellular communication, transfer signals from the extracellular environment into the intracellular area in a highly coordinated fashion. These kinases start a chain of events that eventually activate particular cellular responses through a complex series of molecular interactions.

2. LITERATURE REVIEW

Lu, S., et.al., (2020) looked into the natural anticancer drug betulinic acid (BA) exhibits biological activity against many human tumor cell lines while posing minimal harm to normal cells. However, the compound's short half-life and high hydrophobicity restrict its clinical utility. In this case, gelatin-based dual-targeted BA nanoparticles show promise in providing a solution. To make hydrophobic BA more soluble and extend its in vivo circulation duration, it is put into cyclodextrin. By improving permeability and retention, the nanoscale drug delivery methods passively target the tumor tissue areas while also potentially increasing the bioavailability and anticancer efficacy of BA. Gelatin's RGD sequence is capable of precisely identifying tumor cells and delivering substances inside of them. Nuclear magnetic resonance, Fourier transform infrared, transmission electron microscopy, and other techniques were used to characterize the nanoparticles. Furthermore, they used mouse xenograft tumors and cell-based assays to examine the anticancer activity of the nanoparticles, demonstrating that betulinic acid/gelatin- γ -cyclodextrin nanoparticles had a greater tumor-inhibition impact than betulinic acid/ γ -cyclodextrin inclusion compound.

Wang, J., & Shi, Y. M. (2023) investigated that globally, the number of people afflicted with cancer is rising yearly, but multidrug resistance has made cancer therapy more difficult in recent years, necessitating the urgent need for new chemotherapeutics. Within the kingdom of plants, betulin and betulinic acid are widely distributed pentacyclic triterpenes of the lupane class. Remarkably, betulin and betulinic acid hybrids have been found as attractive candidates to investigate new anticancer chemotherapeutics since these derivatives may be able to overcome the side effects of many drugs, minimize toxicity, and increase efficacy. This review describes the advancements made in the investigation of betulin and betulinic acid hybrids' anticancer potential between 2012 to 2022. The structure–activity connection and mechanisms of action were also covered.

Jiang, W., et.al., (2021) examined birch can be used to produce betulinic acid (BA), a pentacyclic triterpene molecule, by chemical synthesis, biotransformation, and separation. The primary mechanisms by which BA exerts its antitumor activity are through inducing mitochondrial oxidative stress, regulating specificity protein transcription factors, and inhibiting nuclear factor- κ B and signal transducer and activator of transcription 3 signaling pathways. Moreover, BA may make cancer cells more susceptible to the effects of other chemotherapeutic medications. According to recent research, BA has an anticancer effect on a variety of tumor disorders. This research reviews BA's anticancer mechanism and how it might be used to treat tumor illnesses.

Rath, S. K., et.al., (2024) studied in an effort to increase betulinic acid's (BA) anti-cancer effectiveness, a number of C-30 derivatives were thought of and created using a unique synthetic method. By using the MTT assay against six distinct human cancer cell lines, the cytotoxic activity of each derivative was assessed: prostate (PC3), lung (A549), human hepatocellular carcinoma (HepG2), human leukemia (Molt-4), pancreatic (Panc-1), bladder (MCF-7). Based on the findings, compound 16 was found to be the most promising cytotoxic agent against A549, MCF-7, and PC3 cancer cell lines, with IC₅₀ values of 7.43 μ M, 9.1 μ M, and 9.64 μ M, respectively. Compound 16 caused substantial

cell death by stopping the cell cycle in the G1 phase and triggering apoptosis in A549 cells, according to a second mechanistic investigation.

Mukherjee, B., et al., (2020) concluded early in the 1990s, betulinic acid (BA) was found to be a cytotoxic agent. Subsequently, this substance has been thoroughly investigated to determine its antiproliferative effectiveness. Its low water solubility led to various derivatizations to increase its bioavailability and the discovery of extremely cytotoxic analogues that were lethal to cancer cells. Numerous efforts were made to administer several of these compounds of betulinic acid using innovative drug delivery methods in an effort to increase dose effectiveness, decrease undesirable side effects, and improve therapeutic efficacy. This work has covered a variety of betulinic acid derivatives with noteworthy anticancer characteristics and their Nano formulated delivery systems to fight different types of cancer.

3. RESEARCH METHODOLOGY

3.1 Research Design

To assess the bioactivity, selectivity, and inhibitory potency of betulinic acid and its derivatives, the study uses a quantitative research design. In vitro assays are incorporated into the design to gauge how different compounds affect both cancer and normal cell lines. The main goal is to compare each derivative's efficacy, selectivity, and cytotoxicity to a control.

3.2 Data Collection

During the data collection process, betulinic acid and its derivatives were applied at a concentration of 10 μM to both cancer cell lines (Cancer Cell Line A and B) and normal cell lines (Normal Cell Line A and B). The percentage of cell viability and the percentage of cancer cell proliferation inhibition are the main data points gathered. Standard assays were used to quantify the viability of the cells, and proliferation assays were used to evaluate the potency of the inhibition.

3.3 Data Analysis

In order to analyze the data, the percentages of inhibition and cell viability for each chemical were determined. The relative efficacy of each derivative in lowering cancer cell viability and preventing proliferation was assessed through comparative analysis. The results were interpreted using statistical techniques, such as mean comparisons and graphical representation, and the most promising variants were determined by their efficacy and selectivity.

4. DATA ANALYSIS

4.1 Bioactivity Screening of Betulinic Acid Derivatives

Table 1 demonstrates how different betulinic acid and its derivatives work to target cancer cells. The cytotoxicity of betulinic acid in Cancer Cell Line A and B is moderate, as indicated by their respective cell viability rates of 85% and 78%. With a significant decrease in cell viability to 30% and 35% in the respective cell lines, derivative 2 is the most powerful of the derivatives. With 50% and 45% cell viability, respectively, Derivative 1 exhibits impressive efficacy while being less potent than Derivative 2. Even while Derivative 3 isn't as strong as Derivative 2, it nevertheless lowers cell viability to 40% and 50%. Derivative 2 is the most promising choice overall for further investigation due to its improved potential to inhibit cancer cell viability.

Table 1: Percentage of Cancer Cell Survival Following Betulinic Acid Derivative Therapy

Compound	Concentration (μM)	% Cell Viability (Cancer Cell Line A)	% Cell Viability (Cancer Cell Line B)
Betulinic Acid	10	85%	78%
Derivative 1	10	50%	45%
Derivative 2	10	30%	35%
Derivative 3	10	40%	50%
Control (Vehicle)	-	100%	100%




Figure 1: Percentage of Cancer Cell Survival Following Betulinic Acid Derivative Therapy

4.2 Selectivity of Derivatives for Cancer Cells vs. Normal Cells

The selectivity of betulinic acid and its derivatives against cancer cells in comparison to normal cells is shown in Table 2. With 95% viability in Normal Cell Line A and 90% in Normal Cell Line B, betulinic acid exhibits minimal toxicity to normal cells at a dosage of 10 μM , suggesting a relatively low selectivity for cancer cells. Additionally, displaying some selectivity, Derivative 1's viability in Normal Cell Lines A and B is 75% and 70%, respectively. With 60% and 65% vitality in the normal cell lines, derivative 2 shows stronger selectivity, indicating that it is more effective at targeting cancer cells while maintaining the health of normal cells. Compared to the other derivatives, Derivative 3 exhibits a stronger impact on normal cells, as evidenced by its reduced selectivity for cancer cells, with 80% and 85% vitality in Normal Cell Lines A and B, respectively. Derivative 2 is the most selective of the chemicals evaluated because it exhibits the best overall balance between reduced impact on normal cells and efficacy in cancer cells.

Table 2: Percentage of Cell Viability in Normal Cells

Compound	Concentration (μM)	% Cell Viability (Normal Cell Line A)	% Cell Viability (Normal Cell Line B)
Betulinic Acid	10	95%	90%
Derivative 1	10	75%	70%
Derivative 2	10	60%	65%
Derivative 3	10	80%	85%
Control (Vehicle)	-	100%	100%




Figure 2: Graphical Representation of Percentage of Cell Viability in Normal Cells

4.3 Comparison of Inhibition Potency

The ability of betulinic acid and its derivatives to inhibit the multiplication of cancer cells is shown in Table 3. Betulinic acid shows very little inhibition in Cancer Cell Lines A and B at 10 µM; the percentages are just 15% and 22%, respectively. With 50% and 55% inhibition, derivative 1 demonstrates a notable improvement in its capacity to obstruct the proliferation of cancer cells. With 70% and 65% inhibition in Cancer Cell Lines A and B, respectively, derivative 2 exhibits the highest level of inhibition, indicating that it is the most successful in stopping the growth of cancer cells. Derivative 3 is less successful than Derivative 2, although it still exhibits significant inhibition in the corresponding cell lines, with 60% and 50%, respectively. Derivative 2 is the most effective in stopping the growth of cancer cells overall, suggesting that it could be a prime choice for additional research and development in cancer treatment.

Table 3: The percentage of cancer cells inhibited from proliferating

Compound	Concentration (µM)	% Inhibition (Cancer Cell Line A)	% Inhibition (Cancer Cell Line B)
Betulinic Acid	10	15%	22%
Derivative 1	10	50%	55%
Derivative 2	10	70%	65%
Derivative 3	10	60%	50%
Control (Vehicle)	-	0%	0%




Figure 3: Graphical Presentation of Percentage of Cancer Cell Survival Following Betulinic Acid Derivative Therapy

5. CONCLUSION

Significant new information about the potential of betulinic acid and its derivatives for targeted cancer treatment has been revealed by this investigation. Derivative 2 is the most effective of the examined substances; it significantly lowers the viability of cancer cells and exhibits superior inhibition of cell proliferation, especially in cancer cell lines A and B. Additionally, this derivative shows good selectivity, efficiently targeting cancer cells while retaining a comparatively high vitality in normal cell lines. On the other hand, the effectiveness and selectivity of different compounds varies. The findings emphasize betulinic acid derivatives' potential as attractive candidates for more research and development in cancer therapy. Specifically, Derivative 2's ability to target cancer cells specifically while causing the least amount of damage to normal cells is noteworthy.

REFERENCES

1. Wu, Q., Dhir, R. & Wells, A. (2012). Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. *Mol Cancer* 11(3) doi: 10.1186/1476-4598
2. Tebbutt, N., Pedersen, M. W. & Johns, T. G. (2013). Targeting the ERBB family in cancer: couples therapy. *Nature Reviews Cancer* 13: 663-73
3. Rayees, S., Sharma, R., Singh, G., Najjar, I. A., Singh, A., Ahamad, D. B., Sharma, S. C., Tikoo, M. K., Gupta, V. K. & Sangwan, P. L. (2013). Acute, sub-acute and general pharmacological evaluation of 5-(3,

- 4-methylenedioxyphenyl)-4-ethyl-2E, 4E- pentadienoic acid piperidide (SK-20): A novel drug bioavailability enhancer. *Environmental toxicology and pharmacology* 35: 347-59
4. Lu, S., Fan, X., Wang, H., Zhao, Y., Zhao, W., Li, M., ... & Sun, T. (2020). Synthesis of gelatin-based dual-targeted nanoparticles of betulinic acid for antitumor therapy. *ACS Applied Bio Materials*, 3(6), 3518-3525.
 5. Wang, J., & Shi, Y. M. (2023). Recent updates on anticancer activity of betulin and betulinic acid hybrids (a review). *Russian Journal of General Chemistry*, 93(3), 610-627.
 6. Jiang, W., Li, X., Dong, S., & Zhou, W. (2021). Betulinic acid in the treatment of tumour diseases: Application and research progress. *Biomedicine & Pharmacotherapy*, 142, 111990.
 7. Rath, S. K., Nagar, R. K., Das, S., Yadav, G., Mukherjee, D., Singh, B., ... & Sangwan, P. L. (2024). C-30 analogues of betulinic acid as potent cytotoxic agents: design, synthesis, biological evaluation and in-silico studies. *Journal of Biomolecular Structure and Dynamics*, 1-14.
 8. Mukherjee, B., Al Hoque, A., Dutta, D., Paul, B., Mukherjee, A., & Mallick, S. (2020). Nano formulated drug delivery of potential betulinic acid derivatives: A promising approach toward cancer therapy. *Nanomedicine for Bio actives: Healthcare Applications*, 127-153.
 9. Guo, W. B., Zhang, H., Yan, W. Q., Liu, Y. M., Zhou, F., Cai, D. S., ... & Lei, H. M. (2020). Design, synthesis, and biological evaluation of ligustrazine-betulin amino-acid/dipeptide derivatives as anti-tumor agents. *European Journal of Medicinal Chemistry*, 185, 111839.
 10. Rzepka, Z., Bębenek, E., Chrobak, E., & Wrześniok, D. (2022). Synthesis and anticancer activity of indole-functionalized derivatives of betulin. *Pharmaceutics*, 14(11), 2372.
 11. Liang, Y., Zhu, M., Xu, T., Ding, W., Chen, M., Wang, Y., & Zheng, J. (2023). A Novel Betulinic Acid Analogue: Synthesis, Solubility, Antitumor Activity and Pharmacokinetic Study in Rats. *Molecules*, 28(15), 5715.
 12. Suárez-Rozas, C., & Cassels, B. K. (2021). Betulinic acid. In *A Centum of Valuable Plant Bioactives* (pp. 117-142). Academic Press.
 13. Garces de Couto, N. M., Willig, J. B., Ruaro, T. C., de Oliveira, D. L., Buffon, A., Pilger, D. A., ... & Gnoatto, S. C. (2020). Betulinic acid and brosimine B hybrid derivatives as potential agents against Female cancers. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*, 20(5), 622-633.
 14. Lombrea, A., Watz, C. G., Bora, L., Dehelean, C. A., Diaconeasa, Z., Dinu, S., ... & Danciu, C. (2023). Enhanced Cytotoxicity and Antimelanoma Activity of Novel Semisynthetic Derivatives of Betulinic Acid with Indole Conjugation. *Plants*, 13(1), 36.
 15. Li, Y., Wang, Y., Gao, L., Tan, Y., Cai, J., Ye, Z., ... & Chen, Q. (2022). Betulinic acid self-assembled nanoparticles for effective treatment of glioblastoma. *Journal of nanobiotechnology*, 20(1), 39.
